Longboard Pharmaceuticals, Inc.
LBPHDelisted Dec 2, 2024- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001832168
Longboard Pharmaceuticals, Inc. was delisted on Dec 2, 2024; its insiders filed their last Form 4 on Dec 2, 2024; 125 institutions reported holding it in 13F filings for Q3 2024, worth $1.33B in total; Viking Global Investors was the only superinvestor holding it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Longboard Pharmaceuticals, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Longboard Pharmaceuticals, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Schneider Phillip M | Director | – | Dec 2, 2024 | 0 |
| Sekhri Paul J | Director | – | Dec 2, 2024 | 0 |
| Kaye Randall | Executive Vice President & CMO | 0 | Dec 2, 2024 | 0 |
| Roberts Brandi | Executive VP and CFO | 15,090 | Dec 2, 2024 | 0 |
| Aurentz Vincent | Director | – | Dec 2, 2024 | 0 |
| Lind Kevin Robert | President and CEO | 0 | Dec 2, 2024 | 0 |
| Lynch Casey | Director | – | Dec 2, 2024 | 0 |
| Le Goff Corinne | Director | – | Dec 2, 2024 | 0 |
| Arena Pharmaceuticals Inc | Other: Former 10% Owner | 0 | Jan 29, 2024 | 0 |
| Tiller Jane | Director | – | May 26, 2023 | 0 |
| Perera Philip | CMO | – | Feb 11, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jan 29, 2024 (view filing) | Jan 25 | 4 days | Arena Pharmaceuticals IncOther: Former 10% Owner | SSaleVoting Common Stock | −3.98M | $24.25 | −$96.5M | −100.0%0 after | |
| Aug 13, 2024 (view filing) | Jan 23 | 203 daysLate | Kaye RandallCMO | PPurchase | +100 | $24.82 | +$2.48K | New position100 after | 10b5-1 |
| Aug 13, 2024 (view filing) | Jun 25 | 49 daysLate | Kaye RandallCMO | SSale | −100 | $20.87 | −$2.09K | −100.0%0 after | 10b5-1 |
| Aug 13, 2024 (view filing) | Aug 12 | 1 day | Kaye RandallCMO | SSale | −16.7K | $34.73 | −$578.8K | −48.2%17.9K after | 2 lots10b5-1 |
| Sep 16, 2024 (view filing) | Sep 16 | Same day | Kaye RandallCMO | SSale | −16.7K | $31.64 | −$527.3K | −48.2%17.9K after | 4 lots10b5-1 |
| Oct 16, 2024 (view filing) | Oct 15 | 1 day | Kaye RandallCMO | SSale | −16.7K | $59.04 | −$984.0K | −48.2%17.9K after | 10b5-1 |